Worth reading
50Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
140
¥ million (year-on-year change in operating loss)Wording
Conditional
How definitive the wording is.Contents of this document
Earnings presentationQ3 FY20268 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥274 million-10.7%
Operating profit¥-383 million operating loss
Ordinary income¥-386 million ordinary loss
Net income-391 Millions of yen quarterly net loss
Selling, general and administrative expenses¥549 million; selling, general and administrative expense ratio to revenue: not_disclosed
Full-year earnings forecast
Net Sales
¥1,035 million
Operating loss
¥-356 million
Ordinary income
¥175 million
Net income for the current fiscal year
¥146 million
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales26.5%
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Progressing in line with the initial plan (third quarter) / Full-year forecast unchangedBreakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- RevenueDecreased by ¥32 million from ¥307 million in the previous year to ¥274 million
- Cost of salesUp ¥28 million year on year
- Gross profitDown ¥60 million year on year
- SG&A expensesUp ¥79 million year on year
- Research and development costs¥267 million
- Personnel expenses¥203 million
- Other SG&A expenses¥78 million
New initiatives
- Full-scale provision of biofoundry services from April 2027 onward
- Expansion into an integrated industrial platform business based on the medium- to long-term vision
- Acquisition of a license for NMN production technology and a policy to begin OEM production in 2027
- Construction of a semicommercial plant and advancement of biofuel-related projects
Key KPIsA metric the company considers important as a management benchmark.
- Total number of pipeline projects16 Cases, products, and projects
- Production demonstration projects advanced by the development-oriented biofoundry17 Engagements
- Number of targets for the development-oriented biofoundry3 Engagements
- Number of targets for the production-oriented biofoundry10 Product
- Number of targets for technology packages3 PJ
Segment results
Development-oriented biofoundry
Net Sales¥91 million
Year on year against the same period last year-13.3%
Production-oriented biofoundry
Net Sales¥6 million
Year on year against the same period last year+200.0%
Technology package
Net Sales¥177 million
Year on year against the same period last year-11.1%
Medium-term management plan targets
Target for the fiscal year ending September 2031. Specific target figures are not disclosed.Market Size / Share
Target sales of ¥11.9 trillion from biomanufacturing by Japanese companies in 2040; 10% global shareCapital expenditures
¥404 million increase in construction in progress from the end of the previous fiscal year
| Item | Details |
|---|---|
| Document type | Earnings presentation |
| Fiscal Period Covered | Q3 FY2026 |
| Net Sales | ¥274 million (YoY -10.7%) |
| Operating profit | ¥-383 million (operating loss) |
| Ordinary income | ¥-386 million (ordinary loss) |
| Net income | -391 Millions of yen (quarterly net loss) |
| Selling, general and administrative expenses | ¥549 million; selling, general and administrative expense ratio to revenue: not_disclosed |
| Full-year earnings forecast | Net Sales ¥1,035 million / Operating loss ¥-356 million / Ordinary income ¥175 million / Net income for the current fiscal year ¥146 million |
| Progress against full-year forecast | Net Sales 26.5% / Operating loss Not disclosed / Ordinary income Not disclosed / Net income for the current fiscal year Not disclosed |
| Self-assessment against the plan | Progressing in line with the initial plan (third quarter) / Full-year forecast unchanged |
| Segment results | Development-oriented biofoundry Net Sales ¥91 million / yoy_pct ¥-13.3 million / Production-oriented biofoundry Net Sales ¥6 million / yoy_pct ¥200 million / Technology package Net Sales ¥177 million / yoy_pct ¥-11.1 million |
| Breakdown of Factors Affecting the Change | Factors Revenue / Amount Decreased by ¥32 million from ¥307 million in the previous year to ¥274 million, Factors Cost of sales / Amount Up ¥28 million year on year, Factors Gross profit / Amount Down ¥60 million year on year, Factors SG&A expenses / Amount Up ¥79 million year on year, Factors Research and development costs / Amount ¥267 million, Factors Personnel expenses / Amount ¥203 million, Factors Other SG&A expenses / Amount ¥78 million |
| Key KPIs | Indicator name Total number of pipeline projects / Value 16 Cases, products, and projects / Year on year against the same period last year Not disclosed, Indicator name Production demonstration projects advanced by the development-oriented biofoundry / Value 17 Engagements / Year on year against the same period last year Not disclosed, Indicator name Number of targets for the development-oriented biofoundry / Value 3 Engagements / Year on year against the same period last year Not disclosed, Indicator name Number of targets for the production-oriented biofoundry / Value 10 Product / Year on year against the same period last year Not disclosed, Indicator name Number of targets for technology packages / Value 3 PJ / Year on year against the same period last year Not disclosed |
| Medium-term management plan targets | Target for the fiscal year ending September 2031. Specific target figures are not disclosed. |
| Capital expenditures | ¥404 million (increase in construction in progress from the end of the previous fiscal year) |
| Market Size / Share | Target sales of ¥11.9 trillion from biomanufacturing by Japanese companies in 2040; 10% global share |
| New initiatives | Full-scale provision of biofoundry services from April 2027 onward, Expansion into an integrated industrial platform business based on the medium- to long-term vision, Acquisition of a license for NMN production technology and a policy to begin OEM production in 2027, Construction of a semicommercial plant and advancement of biofuel-related projects |
Items this document does not state (14)
Gross Profit MarginOperating profit marginResults for the three months of the current quarterUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesOrders received and order backlogKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue decreased because the previous year included a high proportion of one-time payments from a large technology package project. The widening operating loss was primarily attributed to a higher cost ratio and increased selling, general and administrative expenses due to front-loaded investments in pipeline development, hiring, and plant construction.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.